State of the art biological therapies in pancreatic cancer - Wikidata - wikimedia - TriplyDB

State of the art biological therapies in pancreatic cancer

State of the art biological therapies in pancreatic cancer

http://www.wikidata.org/entity/Q26769941

about

Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression.Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.Study on the mitochondrial apoptosis pathways of small cell lung cancer H446 cells induced by Trichinella spiralis muscle larvae ESPs.Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics.LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer

P2860

Q33803923-688000E0-434D-40B9-8D38-A3641826F0AE Q37157946-5D86B1FC-556A-4B4C-A1F9-5BB994E1F94B Q38665197-69B58361-B3E9-4695-A5D1-1F302A81D6F0 Q47217912-36D909F2-99B6-408A-B03B-DE14553004AF Q50959584-8014C641-46EA-4D06-B8CC-6581B18799D5 Q54977145-7474D69F-3FBA-421D-87E3-15FD6BC2FC88 Q58725212-7C50BD98-7BBA-4D19-9EF7-4E8B37333976

P2860

State of the art biological therapies in pancreatic cancer

http://www.wikidata.org/entity/Q26769941

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

State of the art biological therapies in pancreatic cancer

@ast

State of the art biological therapies in pancreatic cancer

@en

State of the art biological therapies in pancreatic cancer

@nl

type

label

State of the art biological therapies in pancreatic cancer

@ast

State of the art biological therapies in pancreatic cancer

@en

State of the art biological therapies in pancreatic cancer

@nl

prefLabel

State of the art biological therapies in pancreatic cancer

@ast

State of the art biological therapies in pancreatic cancer

@en

State of the art biological therapies in pancreatic cancer

@nl

P1433

Q26769941-A05588E2-A35B-44E0-B6BD-F71F2DAD6CDE

P1476

Q26769941-541EABEE-C325-4EF7-93AF-D79424FE48F1

P2093

Q26769941-051EFAE2-3534-48E5-8467-15BFE0AC48EF

Q26769941-1704EF8C-87FB-4F8B-80D8-6FBCDECF54C5

Q26769941-2EED41F3-A4D1-4D68-B04A-4C2FFC00FE96

Q26769941-349B56C7-678E-4C64-B482-43611B8E9472

Q26769941-5B85FFCD-48FB-41D0-BE1E-FB6523298D80

Q26769941-6101F072-B5AA-4C95-B7AC-8E6DA77F5BED

Q26769941-CAC5588D-3FA5-48E4-B0AF-B7B5BF5568B2

Q26769941-E5BDEEBF-18E0-40AC-BE4E-B75349E42616

Q26769941-F7B8F79B-D8D5-4208-BBC9-976E06CAFAA2

P2860

Q26769941-037E6E3B-EB00-44A8-8F9C-5BF36A6A4B6B

Q26769941-043446AC-86D1-4BF4-9536-2D69DEFE13D5

Q26769941-051B13C3-F166-4B68-B1A9-BF68C468A487

Q26769941-0558E6E0-6F7A-4EA3-971F-AE2E543646DE

Q26769941-0C4B2244-3A2B-4907-A16C-423AA9520B11

Q26769941-0E69851A-4FB5-4495-9EE6-BF54E8976439

Q26769941-1275965B-C566-4C93-A932-63E2289E030E

Q26769941-14095738-B45E-4887-B02C-F7B6B288EB81

Q26769941-14891B2A-B8DB-4442-BD86-3547D2E55D17

Q26769941-15FF4D7B-53B5-4D33-849E-7634C7BD0FE6

P304

Q26769941-F64B6531-0BB2-49C0-92E2-4E39924B8636

P31

Q26769941-E11BF3CB-8B9E-441F-849A-9E6815E1506B

P356

Q26769941-1626D8BE-EBBB-45B8-B3CC-24CA83E4DB1D

P407

Q26769941-DF42FD4B-CA58-45AE-8837-31B9D89B2FD3

P433

Q26769941-AAD82985-B9D3-4B86-BA0F-394604C3DF10

P478

Q26769941-C07E068C-B8A6-4C74-A22B-95D36E01AFEA

P50

Q26769941-AF1CA21D-CB89-4177-A93B-4A6A05CB4B8A

Q26769941-E1B959F9-2C88-46C1-890F-9EFDB9A18FF7

P577

Q26769941-66B50127-ECB7-44D4-9478-91A2AE343816

P5875

Q26769941-FBF7F90E-D395-47EA-AD79-28BC87B167DC

P698

Q26769941-740DFFBF-112D-45CD-9975-F467F9A2D794

P932

Q26769941-22B1690D-8FAC-4A5B-B6A1-4656A6EE16F4

P356

P1433

World journal of gastrointestinal oncology

P1476

State of the art biological therapies in pancreatic cancer

@en

P2093

Andrea Palloni

http://www.w3.org/2001/XMLSchema#string

Claudio Ricci

http://www.w3.org/2001/XMLSchema#string

Donatella Santini

http://www.w3.org/2001/XMLSchema#string

Elisa Grassi

http://www.w3.org/2001/XMLSchema#string

Mariacristina Di Marco

http://www.w3.org/2001/XMLSchema#string

Marina Macchini

http://www.w3.org/2001/XMLSchema#string

Riccardo Casadei

http://www.w3.org/2001/XMLSchema#string

Riccardo Panzacchi

http://www.w3.org/2001/XMLSchema#string

Silvia Vecchiarelli

http://www.w3.org/2001/XMLSchema#string

P2860

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

International network of cancer genome projects.

Targeting the RAS oncogene.

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Cancer statistics, 2015

RAS oncogenes: weaving a tumorigenic web

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

P304

55-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4251/WJGO.V8.I1.55

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290503329

http://www.w3.org/2001/XMLSchema#string

P698

26798437

http://www.w3.org/2001/XMLSchema#string

P932

4714146

http://www.w3.org/2001/XMLSchema#string